Zobrazeno 1 - 10
of 71
pro vyhledávání: '"Ananda S. Bandyopadhyay"'
Autor:
Rahnuma Wahid, Laina Mercer, Chris Gast, Tirza De Leon, Xavier Sáez-Llorens, Alan Fix, Andrew Macadam, Laura Stephens, Konstantin Chumakov, Saskia L. Smits, Marta Murreddu, Jennifer L. Konopka-Anstadt, M. Steven Oberste, Cara C. Burns, Raul Andino, Novilia Sjafri Bachtiar, Erman Tritama, Ananda S. Bandyopadhyay, Gabriela Aguirre, Ricardo Rüttimann, John O. Konz
Publikováno v:
npj Vaccines, Vol 7, Iss 1, Pp 1-11 (2022)
Abstract Novel oral poliovirus vaccine type 2 (nOPV2) is being developed to reduce the rare occurrence of disease and outbreaks associated with the genetic instability of the Sabin vaccine strains. Children aged 1 to 5 years were enrolled in two rela
Externí odkaz:
https://doaj.org/article/a5bc437be7da4f459a47f98cae18af83
Autor:
Ananda S. Bandyopadhyay, Miguel O'Ryan
Publikováno v:
The Lancet Regional Health. Western Pacific, Vol 11, Iss , Pp 100159- (2021)
Externí odkaz:
https://doaj.org/article/54294a1527ae49018d1574bc371ef8ab
Autor:
Ananda S. Bandyopadhyay, Harpal Singh, Jacqueline Fournier-Caruana, John F. Modlin, Jay Wenger, Jeffrey Partridge, Roland W. Sutter, Michel J. Zaffran
Publikováno v:
Emerging Infectious Diseases, Vol 25, Iss 7, Pp 1363-1369 (2019)
The Global Polio Eradication Initiative continues to make progress toward the eradication target. Indigenous wild poliovirus (WPV) type 2 was last detected in 1999, WPV type 3 was last detected in 2012, and over the past 2 years WPV type 1 has been d
Externí odkaz:
https://doaj.org/article/a97ca2fcd0fe4c29971e51fe421a8623
Publikováno v:
PLOS Global Public Health, Vol 4, Iss 2, p e0002920 (2024)
Externí odkaz:
https://doaj.org/article/48a32cf7aa274e8eb1bacbd2516e016f
Autor:
Ananda S Bandyopadhyay, Natalia A. Molodecky, Rana M. Safdar, Hemant Shukla, Isobel M. Blake, Jamal A. Ahmed, Abdirahman Mahamud, Arshad Quddus, Michel Zaffran, Nicholas C. Grassly, Roland W. Sutter, Hamid Jafari
Publikováno v:
A104
A93
Vaccine
A93
Vaccine
Background Since July 2019, Pakistan and Afghanistan have been facing an outbreak of serotype-2 circulating vaccine derived poliovirus (cVDPV2) in addition to continued transmission of serotype-1 wild poliovirus (WPV1) and SARS-CoV-2 in 2020. Underst
Autor:
Rahnuma Wahid, Laina D Mercer, Tirza De Leon, Rodrigo DeAntonio, Xavier Sáez-Llorens, Andrew Macadam, Konstantin Chumakov, Jeroen Strating, Björn Koel, Jennifer L Konopka-Anstadt, M Steven Oberste, Cara C Burns, Raul Andino, Erman Tritama, Ananda S Bandyopadhyay, Gabriela Aguirre, Ricardo Rüttimann, Chris Gast, John O Konz
Publikováno v:
The Lancet Microbe. 3:e912-e921
Sabin strains used in oral poliovirus vaccines (OPV) can revert to virulence and, in rare instances, cause disease or generate vaccine-derived strains leading to outbreaks in areas of low immunisation coverage. A novel OPV2 (nOPV2) was designed to st
Autor:
Javier Martin, Cara C. Burns, Jaume Jorba, Lester M. Shulman, Andrew Macadam, Dimitra Klapsa, Manasi Majumdar, James Bullows, Ann Frolov, Ryan Mate, Erika Bujaki, Christina J. Castro, Kelley Bullard, John Konz, Kaija Hawes, Jillian Gauld, Isobel M. Blake, Laina D. Mercer, Feyrouz Kurji, Arie Voorman, Ousmane M. Diop, M. Steven Oberste, John Modlin, Grace Macklin, Martin Eisenhawer, Ananda S. Bandyopadhyay, Simona Zipursky
Publikováno v:
MMWR. Morbidity and Mortality Weekly Report. 71:786-790
The emergence and international spread of neurovirulent circulating vaccine-derived polioviruses (cVDPVs) across multiple countries in Africa and Asia in recent years pose a major challenge to the goal of eradicating all forms of polioviruses. Approx
Autor:
Kebba Touray, Sarah Wanyoike, Samuel Okiror, Nicksy Gumede, Ananda S Bandyopadhyay, Modjirom Ndoutabe, Ondrej Mach, Laura V Cooper, Alejandro Ramirez-Gonzalez, Pascal Mkanda, Nicholas C. Grassly, Isobel M. Blake
Publikováno v:
The Lancet. Infectious Diseases
Summary Background Expanding outbreaks of circulating vaccine-derived type 2 poliovirus (cVDPV2) across Africa after the global withdrawal of trivalent oral poliovirus vaccine (OPV) in 2016 are delaying global polio eradication. We aimed to assess th
Publikováno v:
The Journal of Infectious Diseases.
Serotype 2 oral poliovirus vaccine (OPV2) can revert to regain wild-type neurovirulence and spread to cause emergences of vaccine-derived poliovirus (VDPV2). After its global withdrawal from routine immunization in 2016, outbreak response use has cre
Autor:
Khaelqu Zaman, Ananda S Bandyopadhyay, Masuma Hoque, Christopher Gast, Mohammad Yunus, Khondoker M Jamil, Bernardo A Mainou, Jennifer L Konopka-Anstadt, William S Hendley, Annelet Vincent, Ralf Clemens, Sue Ann Costa Clemens, Allen G Ross, John D Clemens, Erman Tritama
Publikováno v:
Lancet (London, England).
Type 2 circulating vaccine-derived polioviruses (cVDPV2) from Sabin oral poliovirus vaccines (OPVs) are the leading cause of poliomyelitis. A novel type 2 OPV (nOPV2) has been developed to be more genetically stable with similar tolerability and immu